Navigation Links
Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Date:10/5/2007

FRANKLIN, Mass., Oct. 5 /PRNewswire-FirstCall/ -- Following its recent merger with Echo Therapeutics, Inc., Sontra Medical Corporation (OTC Bulletin Board: SONT), a dual platform-enabled transdermal specialty therapeutics and diagnostics company, today announced that it has changed its corporate name to Echo Therapeutics, Inc., effective Monday, October 8, 2007. In addition, on October 8, 2007, the Company's OTC Bulletin Board ticker symbol will change to "ECTE" and its corporate website address will become http://www.echotx.com.

"Our new name better reflects our expanded strategic focus on building a broad pipeline of advanced topical formulations of FDA-approved specialty pharmaceutical products and next generation needle-free transdermal diagnostics," said Patrick T. Mooney, M.D., CEO of Echo Therapeutics.

About Echo Therapeutics

Echo Therapeutics is a dual platform-enabled, specialty therapeutics and diagnostics company developing an extensive pipeline of advanced topical formulations of FDA-approved products and a suite of needle-free transdermal diagnostics. Echo is developing a next generation, needle-free Continuous Transdermal Glucose Monitor (CTGM) system for use in the diabetes home care and hospital critical care markets. Echo's next generation CTGM system leverages its FDA-approved SonoPrep(R) ultrasound-mediated skin permeation technology platform. Echo is also developing a broad portfolio of advanced topical formulations of well-established, FDA-approved products using its proprietary AzoneTS(TM) dermal penetration technology. Echo has submitted a New Drug Application (NDA) to the FDA for the approval of its lead Azone TS- based product, Durhalieve(TM), for the treatment of corticosteroid responsive dermatoses.

SonoPrep is a registered trademark of Echo Therapeutics, Inc.

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward- looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to our ability to develop, market and sell pharmaceutical or diagnostic products based on our AzoneTS and SonoPrep platform technologies, including AzoneTS-based Durhalieve for corticosteroid responsive dermatoses and a SonoPrep-based continuous transdermal glucose monitor system for the diabetes and hospital critical care markets; the availability of substantial additional equity capital to support our robust research, development and product commercialization activities; and the success of our AzoneTS and SonoPrep business, research, development, and regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-KSB for the year ended December 31, 2006, our most recent quarterly reports on Form 10-QSB, and our current reports on Form 8-K. Echo Therapeutics, Inc. does not undertake to update these forward-looking statements.

10 Forge Parkway

Franklin, MA 02038, USA

Tel: 1+ 877-4-SONTRA (766878)

Fax: 1+ 508-553-8760

http://www.echotx.com

Investor Relations Contacts:

Patrick T. Mooney, M.D., CEO

508-530-0329

pmooney@echotx.com


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Check if your “Favourite medical web-site” is indulging in Quackey
2. Teens turning to Internet for medical queries
3. Robots craft medical history
4. NBE to conduct test for medical students from abroad
5. Air pollution combined with greater medical needs
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. Children! Protecting them from medical mistakes
8. More information sought by patients on medical errors
9. SARS necessitates medical masks
10. Meditation Works Medically
11. Sleep Disorders Could Indicate Other Medical Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... TX (PRWEB) , ... July 24, 2017 , ... ... under the federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted ... of California Department of Health Care Services, will facilitate the development of a ...
(Date:7/24/2017)... ... 24, 2017 , ... A four alarm fire in an ... threatened numerous homes and businesses nearby, causing some 700 individuals to be evacuated, ... Area consulting firm Fire Protection Group, Inc. notes that the report is a ...
(Date:7/24/2017)... ... 24, 2017 , ... The International Essential Tremor Foundation (IETF) will host a ... (ET). The seminar will take place on Saturday, Aug. 26 at the Embassy Suites ... will run from 9 a.m. to 12 p.m., with check-in beginning at 8 a.m. ...
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , a leading ... has partnered with WALLIX to expand its solution to help government contractors ... are a number of ways to address the authentication requirements within NIST SP800-171, ...
(Date:7/24/2017)... PHILADELPHIA (PRWEB) , ... July 24, 2017 , ... ... Health , two organizations that already work hand-in-hand on an Innovation Collaboration program, ... transform the access, quality, experience and cost of the care members and patients ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... 2017  New York City-based market research firm Kalorama Information ... aware of.  From new products to new costs, to the ... recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact Moment Arriving ... the impact the growing population and, to a more extreme ...
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... July 11, 2017  Bayer has awarded grants totaling more ... part of its prestigious Bayer Hemophilia Awards Program (BHAP). Four ... Philadelphia and Uniformed Services University of the ... the winners. Grant recipients were announced last night during a ... 2017 Congress, Berlin, Germany . ...
Breaking Medicine Technology: